• Explore /
  • Poster
  • / Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab  (B) for completely resected early-stage non-small cell lung cancer (NSCLC).

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab  (B) for completely resected early-stage non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

Heather Wakelee

H. A. Wakelee

Stanford University School of Medicine, Stanford, CA

H. A. Wakelee , S. E. Dahlberg , S. M. Keller , D. R. Gandara , S. L. Graziano , N. B. Leighl , A. A. Adjei , J. H. Schiller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer - Local-regional and Adjuvant Therapy/Small Cell

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT00324805

Citation

J Clin Oncol 29: 2011 (suppl; abstr 7013)

Abstract #

7013

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Benjamin J. Solomon

First Author: Heather A. Wakelee

First Author: Yuming Zhu

Poster

2018 ASCO Annual Meeting

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

First Author: Nathaniel R. Evans